BACKGROUND: Hereditary deficiency of adenine phosphoribosyltransferase causes 2,8-dihydroxyadenine (2,8-DHA) nephropathy, a rare condition characterized by formation of 2,8-DHA crystals within renal tubules. Clinical relevance of rodent models of 2,8-DHA crystal nephropathy induced by excessive adenine intake is unknown. METHODS: Using animal models and patient kidney biopsies, we assessed the pathogenic sequelae of 2,8-DHA crystal-induced kidney damage. We also used knockout mice to investigate the role of TNF receptors 1 and 2 (TNFR1 and TNFR2), CD44, or alpha2-HS glycoprotein (AHSG), all of which are involved in the pathogenesis of other types of crystal-induced nephropathies. RESULTS: Adenine-enriched diet in mice induced 2,8-DHA nephropathy, leading to progressive kidney disease, characterized by crystal deposits, tubular injury, inflammation, and fibrosis. Kidney injury depended on crystal size. The smallest crystals were endocytosed by tubular epithelial cells. Crystals of variable size were excreted in urine. Large crystals obstructed whole tubules. Medium-sized crystals induced a particular reparative process that we term extratubulation. In this process, tubular cells, in coordination with macrophages, overgrew and translocated crystals into the interstitium, restoring the tubular luminal patency; this was followed by degradation of interstitial crystals by granulomatous inflammation. Patients with adenine phosphoribosyltransferase deficiency showed similar histopathological findings regarding crystal morphology, crystal clearance, and renal injury. In mice, deletion of Tnfr1 significantly reduced tubular CD44 and annexin two expression, as well as inflammation, thereby ameliorating the disease course. In contrast, genetic deletion of Tnfr2, Cd44, or Ahsg had no effect on the manifestations of 2,8-DHA nephropathy. CONCLUSIONS: Rodent models of the cellular and molecular mechanisms of 2,8-DHA nephropathy and crystal clearance have clinical relevance and offer insight into potential future targets for therapeutic interventions.
BACKGROUND:Hereditary deficiency of adenine phosphoribosyltransferase causes 2,8-dihydroxyadenine (2,8-DHA) nephropathy, a rare condition characterized by formation of 2,8-DHA crystals within renal tubules. Clinical relevance of rodent models of 2,8-DHAcrystal nephropathy induced by excessive adenine intake is unknown. METHODS: Using animal models and patient kidney biopsies, we assessed the pathogenic sequelae of 2,8-DHA crystal-induced kidney damage. We also used knockout mice to investigate the role of TNF receptors 1 and 2 (TNFR1 and TNFR2), CD44, or alpha2-HS glycoprotein (AHSG), all of which are involved in the pathogenesis of other types of crystal-induced nephropathies. RESULTS:Adenine-enriched diet in mice induced 2,8-DHAnephropathy, leading to progressive kidney disease, characterized by crystal deposits, tubular injury, inflammation, and fibrosis. Kidney injury depended on crystal size. The smallest crystals were endocytosed by tubular epithelial cells. Crystals of variable size were excreted in urine. Large crystals obstructed whole tubules. Medium-sized crystals induced a particular reparative process that we term extratubulation. In this process, tubular cells, in coordination with macrophages, overgrew and translocated crystals into the interstitium, restoring the tubular luminal patency; this was followed by degradation of interstitial crystals by granulomatous inflammation. Patients with adenine phosphoribosyltransferase deficiency showed similar histopathological findings regarding crystal morphology, crystal clearance, and renal injury. In mice, deletion of Tnfr1 significantly reduced tubular CD44 and annexin two expression, as well as inflammation, thereby ameliorating the disease course. In contrast, genetic deletion of Tnfr2, Cd44, or Ahsg had no effect on the manifestations of 2,8-DHAnephropathy. CONCLUSIONS: Rodent models of the cellular and molecular mechanisms of 2,8-DHAnephropathy and crystal clearance have clinical relevance and offer insight into potential future targets for therapeutic interventions.
Authors: Kym M Boycott; Taila Hartley; Leslie G Biesecker; Richard A Gibbs; A Micheil Innes; Olaf Riess; John Belmont; Sally L Dunwoodie; Nebojsa Jojic; Timo Lassmann; Deborah Mackay; I Karen Temple; Axel Visel; Gareth Baynam Journal: Cell Date: 2019-03-21 Impact factor: 41.582
Authors: Eva M Buhl; Sonja Djudjaj; Janka Babickova; Barbara M Klinkhammer; Erika Folestad; Erawan Borkham-Kamphorst; Ralf Weiskirchen; Kelly Hudkins; Charles E Alpers; Ulf Eriksson; Jürgen Floege; Peter Boor Journal: Kidney Int Date: 2016-02-18 Impact factor: 10.612
Authors: Kasper M A Rouschop; Joris J T H Roelofs; Nike Claessen; Paula da Costa Martins; Jaap-Jan Zwaginga; Steven T Pals; Jan J Weening; Sandrine Florquin Journal: J Am Soc Nephrol Date: 2005-05-18 Impact factor: 10.121
Authors: W Jahnen-Dechent; T Schinke; A Trindl; W Müller-Esterl; F Sablitzky; S Kaiser; M Blessing Journal: J Biol Chem Date: 1997-12-12 Impact factor: 5.157
Authors: Shrikant R Mulay; Onkar P Kulkarni; Khader V Rupanagudi; Adriana Migliorini; Murthy N Darisipudi; Akosua Vilaysane; Daniel Muruve; Yan Shi; Fay Munro; Helen Liapis; Hans-Joachim Anders Journal: J Clin Invest Date: 2012-12-10 Impact factor: 14.808
Authors: Gerritje J W van der Windt; Cornelis van 't Veer; Sandrine Florquin; Tom van der Poll Journal: Infect Immun Date: 2009-11-09 Impact factor: 3.441
Authors: Femke Waanders; Mirjan M van Timmeren; Coen A Stegeman; Stephan J L Bakker; Harry van Goor Journal: J Pathol Date: 2010-01 Impact factor: 7.996
Authors: Mark R Hanudel; Brian Czaya; Shirley Wong; Maxime Rappaport; Shweta Namjoshi; Kristine Chua; Grace Jung; Victoria Gabayan; Bo Qiao; Elizabeta Nemeth; Tomas Ganz Journal: Kidney Int Date: 2021-11-25 Impact factor: 10.612
Authors: Marcus J Moeller; Rafael Kramann; Twan Lammers; Bernd Hoppe; Eicke Latz; Isis Ludwig-Portugall; Peter Boor; Jürgen Floege; Christian Kurts; Ralf Weiskirchen; Tammo Ostendorf Journal: Front Med (Lausanne) Date: 2022-01-12
Authors: Nassim Bouteldja; Barbara M Klinkhammer; Roman D Bülow; Patrick Droste; Simon W Otten; Saskia Freifrau von Stillfried; Julia Moellmann; Susan M Sheehan; Ron Korstanje; Sylvia Menzel; Peter Bankhead; Matthias Mietsch; Charis Drummer; Michael Lehrke; Rafael Kramann; Jürgen Floege; Peter Boor; Dorit Merhof Journal: J Am Soc Nephrol Date: 2020-11-05 Impact factor: 10.121
Authors: Francesca Solagna; Caterina Tezze; Maja T Lindenmeyer; Shun Lu; Guochao Wu; Shuya Liu; Yu Zhao; Robert Mitchell; Charlotte Meyer; Saleh Omairi; Temel Kilic; Andrea Paolini; Olli Ritvos; Arja Pasternack; Antonios Matsakas; Dominik Kylies; Julian Schulze Zur Wiesch; Jan-Eric Turner; Nicola Wanner; Viji Nair; Felix Eichinger; Rajasree Menon; Ina V Martin; Barbara M Klinkhammer; Elion Hoxha; Clemens D Cohen; Pierre-Louis Tharaux; Peter Boor; Tammo Ostendorf; Matthias Kretzler; Marco Sandri; Oliver Kretz; Victor G Puelles; Ketan Patel; Tobias B Huber Journal: J Clin Invest Date: 2021-06-01 Impact factor: 14.808
Authors: Kyoungrae Kim; Erik M Anderson; Trace Thome; Guanyi Lu; Zachary R Salyers; Tomas A Cort; Kerri A O'Malley; Salvatore T Scali; Terence E Ryan Journal: Am J Physiol Renal Physiol Date: 2021-06-14